antioestrogens

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

Antioestrogens are used in the hormonal treatment of breast cancer. The gold standard is tamoxifen which is primarily an oestrogen receptor antagonist with some agonist acitivity.

Tamoxifen taken for 5 years following surgical treatment is a standard part of the treatment regime for postmenopausal women with hormone-receptor-positive breast cancer. If used in this context then tamoxifen:

  • increases the proportion of women who survive for at least 10 years from about 50% to 60% among those with lymph-node involvement
  • increases the proportion of women who survive for at least 10 years without lymph-node involvement from about 73% to 79%
  • almost halves the risk of development of cancer in the contralateral breast

Reference:

  1. Drug and Therapeutics Bulletin (2003), 41 (8), 57-59.

Last reviewed 01/2018

Links: